SAN DIEGO, November 24, 2015 /PRNewswire/ – ProSciento Inc., a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today the appointment of Meryl Wiernik as Senior Director of CRO Services.
Wiernik joins ProSciento with more than 25 years of experience in clinical operations and global outsourcing management for the CRO and biopharmaceutical industry. In this new management position, Wiernik will lead the strategic expansion of ProSciento’s CRO multi-center management services.
“Meryl has an outstanding track record in senior management roles within the CRO and biopharma industry. Her expertise will be highly impactful as we continue to expand our CRO services while maintaining our science driven, therapeutically focused approach,” said Dr. Linda Morrow, ProSciento COO.
“ProSciento has earned an outstanding reputation in the industry for its metabolism focus and scientific expertise. I’m excited to join this highly respected clinical operations team and to be a part of the strategic growth of their CRO services for biopharmaceutical clients globally,” said Wiernik. “I look forward to building upon the success the company has achieved to date by further expanding its multi-center management services.”
Wiernik is a highly accomplished leader with an extensive track record in developing and executing operational strategies within CRO and biopharmaceutical settings. She was most recently a consultant to the biopharma industry in areas of operations, quality assurance, and vendor management. Prior to that, she was the Vice President of Quality Assurance and Business Excellence for SynteractHCR, Inc., where she oversaw the integration process of global clinical trial conduct for Synteract and Harrison Clinical Research. Wiernik also served in leadership roles for global outsourcing at Teva Pharmaceuticals, Bristol Myers Squibb (BMS) and Amgen. During her 19 year tenure at BMS, she was instrumental in the conceptualization and implementation of the BMS Clinical Laboratory in support of its phase I unit as well as multi-site phase II-IV trials. Wiernik also served in leadership roles for business systems and operations at LabCorp Clinical Trials and Quest Diagnostics.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427